Data Lacking On Inamed’s Lap-Band, Blue Cross TEC Maintains
This article was originally published in The Gray Sheet
Executive Summary
More long-term data is needed to assess the net health outcomes of laparoscopic adjustable gastric banding (LAGB) to treat obesity, according to the BlueCross BlueShield Association's Technology Evaluation Center
You may also be interested in...
Broad Coverage For Lap-Band Helps Grow Allergan’s Obesity Sales
CMS' decision to cover Allergan's Lap-Band laparoscopic adjustable gastric band for Medicare beneficiaries last February helped spark a 33% revenue jump for Allergan's obesity intervention business in 2006
Broad Coverage For Lap-Band Helps Grow Allergan’s Obesity Sales
CMS' decision to cover Allergan's Lap-Band laparoscopic adjustable gastric band for Medicare beneficiaries last February helped spark a 33% revenue jump for Allergan's obesity intervention business in 2006
Gastric band gets Blues’ TEC support
Laparoscopic adjustable gastric banding is "a reasonable choice for a patient considering bariatric surgery" to treat obesity, according to an upcoming report from the BlueCross BlueShield Association's Technology Evaluation Center. The report reverses TEC's 2005 opinion that the procedure - for which Allergan/Inamed's Lap-Band is the only FDA-approved device - did not meet TEC's health benefit criteria when compared to gastric bypass, primarily due to lack of long-term data (1"The Gray Sheet" Sept. 19, 2005, p. 11). While TEC does not make reimbursement decisions, payors often consult the center's assessments...